Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 20, 2007

View Archived Issues

IPI-504 overcomes gefitinib resistance in non-small cell lung cancer cell lines

Velcade's significant efficacy advantage prompts early end of phase III clinical trial

FDA grants orphan drug designation to Infinity and MedImmune's IPI-504 for GIST

MicroIslet and Progenitor sign manufacturing agreement for MicroIslet-P

FDA approves five-day, once-daily regimen of Levaquin for cUTI and AP

University of Nottingham develops possible HCV vaccine

Provectus announces results of phase I metastatic melanoma study

Recent patents describe novel agents for psychiatric disorders

CP-3242: a novel metallo-beta-lactamase inhibitor profiled at the ICAAC meeting

Update on EpiCept's MAA for Ceplene in E.U.

Sosei completes phase II proof-of-principle trial of AD-337 for FMS

Novel therapeutic agents for thrombotic disorders reported in recent Trigen patent

Phase I/II clinical program to study Torisel/Velcade combination in multiple myeloma

FDA accepts Samaritan's IND for SP-6300 in Cushing's syndrome

Targeted Genetics reports results of RAC hearing on phase I/II trial of tgAAC94

Perseus and Brigham sign research agreement for cardiovascular risk predictor PTX3

MorphoSys initiates phase I trial of HuCAL gold-derived fully human antibody

Bristol-Myers begins phase II trial of p38 kinase inhibitor BMS-582949 for psoriasis

Aphios and Boston University awarded development grant for APH-M109

Phase I trial expanded after alvespimycin shows activity in metastatic breast cancer

Meta-analysis: Pioglitazone reduces ischemic cardiovascular risk in diabetes patients

mGlu2/3 receptor activation with LY-2140023 improves schizophrenia symptoms

Positive preclinical results of novel RSV fusion inhibitor TMC-353121

Triple beta-lactam combination effective in Gram-negative sepsis models

FDA grants Preos orphan drug status in hypoparathyroidism indication

E.U. grants Novo Nordisk approval for use of NovoRapid in elderly people

Smaller dose Tamiflu approved in Europe; expanded use of FluMist approved in U.S.

EMEA grants Progen's PI-88 orphan drug designation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...